New French relative assessment method for drug reimbursement has echoes of German system
This article was originally published in SRA
The French health technology assessment agency, the HAS (Haute Autorité de Santé), has published details of a new "relative therapeutic index" mechanism that it plans to use to select medicines for reimbursement on the basis of a comparison with existing products1.
You may also be interested in...
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.